Company intelligence / Profile preview
Oxalo Therapeutics
Chicago, Illinois, United Statesoxalotherapeutics.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Oxalo Therapeutics is developing a first-in-class microbiome-inspired oral peptide therapeutic that mimics Oxalobacter formigenes–driven intestinal oxalate transport to treat primary hyperoxaluria and prevent kidney stones; current public information indicates pre-clinical development and STTR-funded work on an oral peptide drug delivery system without reported human clinical trial results yet.[2][3]
- Therapeutic areas
- NephrologyRare Diseases
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Oxalo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxalo Therapeutics.